Primary treatment of advanced ovarian cancer: how does the 'real world' practice?

Journal Article (Journal Article)

Aims: This study evaluated primary treatment modalities in advanced ovarian cancer according to sociodemographic characteristics and characterized chemotherapy regimens used. Methods: This was a retrospective study of newly diagnosed advanced ovarian, tubal or peritoneal cancer patients at two hospitals from 2011 to 2016. Results: Of 175 women, 41% received neoadjuvant chemotherapy and 59% received primary cytoreductive surgery. Within the neoadjuvant chemotherapy group, 23% did not have a surgical consultation prior to initiating treatment. Women receiving neoadjuvant chemotherapy lived closer to an academic center and more frequently received carboplatin/paclitaxel every 3 weeks. Cytoreductive surgery patients more frequently received intraperitoneal chemotherapy. Conclusion: The authors identified disparities in age, insurance, distance from treatment center and chemotherapy choice in the primary treatment for ovarian cancer.

Full Text

Duke Authors

Cited Authors

  • Craig, AD; Garcia, E; Peters, PN; Chen, L-M; Chapman, JS

Published Date

  • December 2021

Published In

Volume / Issue

  • 17 / 34

Start / End Page

  • 4687 - 4696

PubMed ID

  • 34435878

Electronic International Standard Serial Number (EISSN)

  • 1744-8301

International Standard Serial Number (ISSN)

  • 1479-6694

Digital Object Identifier (DOI)

  • 10.2217/fon-2021-0086


  • eng